SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer. Dr. Parsley will fill a key role on Aires' leadership team and will be responsible for all clinical development activities for Aironite™, the company's lead product for treatment of pulmonary arterial hypertension (PAH).
Dr. Parsley joins Aires from Pfizer where he was the Clinical Lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's approved drug to treat PAH, as well as the additional compounds in Pfizer's pulmonary vascular disease portfolio. Dr. Parsley previously worked at CSL Biotherapies and Encysive Pharmaceuticals, Inc. where he was the Executive Director for Global Medical Affairs and Drug Safety developing an endothelin antagonist for pulmonary hypertension, heart failure and resistant hypertension.
Dr. Parsley is a practicing physician and Board certified in Pulmonary, Internal Medicine, Critical Care and Sleep Medicine. Prior to joining industry, he was an assistant professor and medical director at the University of Texas Medical School at Houston.
"We are excited to welcome Ed to our team," stated Wendy Johnson, President & CEO of Aires. "Ed brings a wealth of experience developing drugs for treatment of PAH and other pulmonary vascular diseases. He is well-known in the PAH community and will make immediate contributions to shaping and executing our clinical development program."
Aires Pharmaceuticals, Inc. is a privately held drug development company located in San Diego developing Aironite™ for cardiopulmonary indications such as pulmonary arterial hypertension. In November 2010, Aires announced a $20M equity financing funded by ProQuest Investments and MPM Capital.